Trial reportNeurology2025
Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI.
Trial report in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05287750 (Brain Diseases on 7.0T Magnetic Resonance Imaging), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Brain Diseases on 7.0T Magnetic Resonance Imaging
Who cites it
2 citing papers in PubMed.
- A Deep-Learning Model for Stroke Subtype Identification in Moyamoya Disease Based on Digital Subtraction Angiography.Translational stroke research · 2026Article
- Molecular and multimodal biomarkers in Moyamoya disease: from pathogenic mechanisms to clinical translation.European journal of medical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesWhile digital subtraction angiography (DSA) is traditionally used for moyamoya disease (MMD) assessment, its invasiveness and limitations necessitate alternative methods. The higher signal-to-noise ratio (SNR) and contrast-to-noise ratio of 7T MRI improve the clarity of the image and retains the details of the structures. We aimed to assess the performance of 7T MRI in identifying hemorrhagic risk features of MMD compared with 3T MRI and DSA.
methodsThis cross-sectional study recruited patients with MMD who underwent both 7T and 3T MRI scans within a 24-hour window, from March 2022 to December 2023. Patients were categorized into hemorrhagic, ischemic, and asymptomatic groups based on standard MRI findings and clinical symptoms. Corresponding DSA images acquired within 90 days were also collected as a comparative benchmark. Hemorrhage risk factors including dilatation and branch extension of the anterior choroidal artery (AChA) and posterior communicating artery (PComA) were assessed and graded on time-of-flight magnetic resonance angiography (TOF-MRA) and DSA images following established protocols. The hemorrhage locations were classified into anterior and posterior circulation groups.
resultsA total of 180 patients (mean age, 43.95 ± 11.02 [SD] years; 53.9% female) were included in the study (hemorrhagic = 51, ischemic = 37, asymptomatic = 92). Notably, 42.4% of AChA and 27.7% of PComA anomalies detected on 7T TOF-MRA were absent on 3T imaging. The 7T TOF-MRA demonstrated a strong correlation with DSA in assessing the AChA stage (weighted κ = 0.891, DISCUSSION: The 7T TOF-MRA visualization of dilatation and branching extension of the AChA and PComA indicates a heightened risk of hemorrhage, suggesting that this imaging technique could serve as a valuable noninvasive tool for identifying hemorrhagic vulnerabilities in MMD. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov, NCT05287750, Brain Diseases on 7.0T Magnetic Resonance Imaging, First Submitted January 2022. clinicaltrials.gov/study/NCT05287750. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that 7T-TOF MRA accurately distinguishes hemorrhagic risk in patients with MMD compared with 3T-TOF MRA and DSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.